Ligand raises 2026 adjusted EPS guidance to $9.50-$9.75 while targeting ~$200M annual capital deployment

Earnings Call Insights: Ligand Pharmaceuticals (LGND) Q3 2026

Management View

• “The third quarter was an important one for Ligand with royalty revenue growing 51% year-over-year to approximately $70 million.” (CEO & Director Todd Davis)
• “We are also raising our adjusted

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.